Skip to main content
Premium Trial:

Request an Annual Quote

TrovaGene Acquires CLIA Lab

NEW YORK (GenomeWeb News) – TrovaGene today said that it has signed a definitive agreement to acquire the clinical lab assets of MultiGen Diagnostics, a privately held molecular diagnostic subsidiary of Bio-ID Diagnostics based in San Diego.

The lab is certified by the State of California in compliance with CLIA and is accredited by the College of American Pathologists.

TrovaGene will issue 750,000 shares of its common stock with an additional earn-out of up to $3.7 million in cash and common stock, subject to the lab achieving specific sales and earnings targets. The acquisition is expected close this quarter.

"We are looking forward to grow MultiGen's existing, multiplexed-sequencing based diagnostic testing business for a variety of infectious diseases," TrovaGene CEO Antonius Schuh said in a statement. "We will explore the feasibility to configure existing MultiGen tests on our trans-renal platform and we plan to leverage the CLIA laboratory operations as a development and commercial platform for novel tests intended to detect minimal residual disease in oncology, based on tumor-specific mutations detectable in a patient's urine."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.